Literature DB >> 33577872

Colorectal Cancer Incidence After Colonoscopy at Ages 45-49 or 50-54 Years.

Maanek Sehgal1, Uri Ladabaum2, Alka Mithal3, Harminder Singh4, Manisha Desai5, Gurkirpal Singh6.   

Abstract

BACKGROUND & AIMS: Colorectal cancer (CRC) incidence at ages younger than 50 years is increasing, leading to proposals to lower the CRC screening initiation age to 45 years. Data on the effectiveness of CRC screening at ages 45-49 years are lacking.
METHODS: We studied the association between undergoing colonoscopy at ages 45-49 or 50-54 years and CRC incidence in a retrospective population-based cohort study using Florida's linked Healthcare Cost and Utilization Project databases with mandated reporting from 2005 to 2017 and Cox models extended for time-varying exposure.
RESULTS: Among 195,600 persons with and 2.6 million without exposure to colonoscopy at ages 45-49 years, 276 and 4844 developed CRC, resulting in CRC incidence rates of 20.8 (95% CI, 18.5-23.4) and 30.6 (95% CI, 29.8-31.5) per 100,000 person-years, respectively. Among 660,248 persons with and 2.4 million without exposure to colonoscopy at ages 50-54 years, 798 and 6757 developed CRC, resulting in CRC incidence rates of 19.0 (95% CI, 17.7-20.4) and 51.9 (95% CI, 50.7-53.1) per 100,000 person-years, respectively. The adjusted hazard ratios for incident CRC after undergoing compared with not undergoing colonoscopy were 0.50 (95% CI, 0.44-0.56) at ages 45-49 years and 0.32 (95% CI, 0.29-0.34) at ages 50-54 years. The results were similar for women and men (hazard ratio, 0.48; 95% CI, 0.40-0.57 and hazard ratio, 0.52; 95% CI, 0.43-0.62 at ages 45-49 years, and hazard ratio, 0.35; 95% CI, 0.31-0.39 and hazard ratio, 0.29; 95% CI, 0.26-0.32 at ages 50-54 years, respectively).
CONCLUSIONS: Colonoscopy at ages 45-49 or 50-54 years was associated with substantial decreases in subsequent CRC incidence. These findings can inform screening guidelines.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colonoscopy; Colorectal Cancer; Incidence; Screening

Year:  2021        PMID: 33577872     DOI: 10.1053/j.gastro.2021.02.015

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

1.  Factors associated with colorectal cancer screening intent and uptake among adult Non-Hispanic Black men.

Authors:  Charles R Rogers; Roger Figueroa; Ellen Brooks; Ethan M Petersen; Carson D Kennedy; Darrell M Gray Ii; Michael Sapienza; Man Hung
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  CT Colonography and Colorectal Carcinoma: Current Trends and Emerging Developments.

Authors:  Monika Kadari; Muhammad Subhan; Nisha Saji Parel; Parimi Vamsi Krishna; Anuradha Gupta; Kamsika Uthayaseelan; Kivonika Uthayaseelan; Naga Anjani Bhaskar Srinivas Sunkara
Journal:  Cureus       Date:  2022-05-11

3.  Oxymatrine Synergistically Enhances Doxorubicin Anticancer Effects in Colorectal Cancer.

Authors:  Di Pan; Wen Zhang; Nenling Zhang; Yini Xu; Yi Chen; Jianqing Peng; Yan Chen; Yanyan Zhang; Xiangchun Shen
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

4.  Disparate age and sex distribution of sessile serrated lesions and conventional adenomas in an outpatient colonoscopy population-implications for colorectal cancer screening?

Authors:  Vidit Lall; Ali Galalah Mostafa Ismail; Oyekoya Taiwo Ayonrinde
Journal:  Int J Colorectal Dis       Date:  2022-06-04       Impact factor: 2.796

5.  Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset.

Authors:  Caroline Himbert; Jane C Figueiredo; David Shibata; Jennifer Ose; Tengda Lin; Lyen C Huang; Anita R Peoples; Courtney L Scaife; Bartley Pickron; Laura Lambert; Jessica N Cohan; Mary Bronner; Seth Felder; Julian Sanchez; Sophie Dessureault; Domenico Coppola; David M Hoffman; Yosef F Nasseri; Robert W Decker; Karen Zaghiyan; Zuri A Murrell; Andrew Hendifar; Jun Gong; Eiman Firoozmand; Alexandra Gangi; Beth A Moore; Kyle G Cologne; Maryliza S El-Masry; Nathan Hinkle; Justin Monroe; Matthew Mutch; Cory Bernadt; Deyali Chatterjee; Mika Sinanan; Stacey A Cohen; Ulrike Wallin; William M Grady; Paul D Lampe; Deepti Reddi; Mukta Krane; Alessandro Fichera; Ravi Moonka; Esther Herpel; Peter Schirmacher; Matthias Kloor; Magnus von Knebel-Doeberitz; Johanna Nattenmueller; Hans-Ulrich Kauczor; Eric Swanson; Jolanta Jedrzkiewicz; Stephanie L Schmit; Biljana Gigic; Alexis B Ulrich; Adetunji T Toriola; Erin M Siegel; Christopher I Li; Cornelia M Ulrich; Sheetal Hardikar
Journal:  Cancers (Basel)       Date:  2021-07-29       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.